1Sheikhi MA, Ebadi A, Talaeizadeh A, et al. Alternative methods to treat nausea and vomiting from cancer chemotherapy [ J ]. Chemother Res Pract,2015 (2015) :818759.
2Kim JS, Kim JY, Lee SJ, et al. Muhicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy - in- duced nausea and vomiting for colorectal cancer[ J ]. Ann Surg Treat Res,2014,87( 1 ) :9 - 13.
3Grassi L, Berardi MA, Ruffilli F, et al. Role of psychosocial variables on chemotherapy - induced nausea and vomiting and health - related quality of life among cancer patients: a European study[ J]. Psychother Psyehosom ,2015,84 (6) :339 - 347.
4Kim KR, Kang G, Ki MS, et al. A randomized, double - blind pilot study of dose comparison of ramosetron to prevent chemotherapy - induced nausea and vomiting [ J ]. Biomed Res Int, 2015 (2015) : 523601.
5Ito Y, Karayama M, Inui N, et al. Aprepitant in patients with ad- vanced non - small - cell lung cancer receiving carboplatin - based chemotherapy[J]. Lung Cancer,2014,84 ( 3 ) :259 - 264.
6Kaushal P, Atri R, Soni A, et al. Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemo- therapy- induced emesis in head and neck cancer patients [ J ]. Ecancermedicalscience, 2015 ( 9 ) : 567.
7Schwartzberg L, Harrow B, Lal LS, et al. Resource utilization for chemotherapy - induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens [ J]. Am Health Drug Benefits ,2015,8 ( 5 ) :273 - 282.
8Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy - and radiotherapy - induced nausea and vomiting: results of the perugia consensus conference[ J]. Ann Onco1,2010,21 (5) :232 - 243.
9Roscoe JA, Morrow GR, Aapro MS, et al. Anticipatory nausea and vomiting[ J]. Support Care Cancer,2011,19(10) :1533 -1538.
10Raedler LA. Akynzeo (Netupitant and Palonosetron), a dual - acting oral agent, approved by the FDA for the prevention of chemotherapy- induced nausea and vomiting [ J ]. Am Health Drug Benefits, 2015,8 ( Spec Feature) :44 - 48.
